CEL-SCI Corporation (NYSEAMERICAN: CVM) has issued a letter to shareholders addressing the confusion about the third phase study results in newly diagnosed advanced primary head and neck cancer released last week.  Multikine demonstrated statistical significance in five-year survival benefit   The company said that its Multikine immunotherapy showed statistically significant five-year […]